Sacco, one of the leading and most historically relevant biotech companies in both research and the production of lactic bacteria and probiotics for the food, nutraceutical and pharmaceutical industries, has recently acquired the majority of Synbiotec, a spin-off company of the University of Camerino specialized in the research and development of probiotics for applications in human and animal nutrition.
The potential synergies between these two companies are numerous: both share the strategic goal of contributing to the improvement of both humans’ and animals’ welfare through the study, research and development of natural ingredients and processes; and both commit to supplying probiotic bacterial strains with the highest levels of quality and innovation always keeping in tune with the demands of a constantly evolving market.
«We are deeply convinced that the synergies existing between the two companies, which have over time had the chance to get to know each other, and which are further reinforced through this acquisition, will lead to the landmark establishment of a pole of excellence in the Italian industry of probiotics for human and animal health. This will also undoubtedly favour research, development and innovation in the production and improvement of products for the well-being of consumers. Another shared fundamental pillar for both companies, which paves the ground for virtuous cooperation, is the cardinal importance both assign to human capital for the achievement of their core goals.” says Martino Verga, CEO of Sacco Srl.
“We are thrilled to be able to share our probiotic research experience with a large international group like Sacco. The strength of its history and its global presence will allow us to explore together new applications for the probiotic market with the shared intention of improving the health and well-being of consumers. The participation of the Sacco group in Synbiotec is a great opportunity for our company, and I am sure it will help us grow and further establish ourselves in the market”, says Maria Cristina Verdenelli, President and Founding Partner of Synbiotec.
Latest News
An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.
The global population is ageing faster than ever before. In 2019, life expectancy at birth reached 72.8 years almost 9 years more than in 1990. In this context, staying healthy
El grupo acelera su estrategia de desarrollo en Sudamérica mediante una doble operación: la adquisición de una empresa uruguaya y la integración total de su filial brasileña. El grupo apunta
La leche es el recurso más valioso en la producción láctea.Solo es posible obtener productos de alta calidad a partir de leche de alta calidad, y en el panorama actual,
“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
Our commitment to sustainability: a review of an evolving journey We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici, Sacco
Indianapolis, Ind., and Yeerongpilly, Queensland, Australia, March 13, 2024 – List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce
Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries, based on tradition, expertise, research, and innovation which sells and distributes its ingredients in more